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As South Africa (SA) braced itself for a second wave of COVID-19 
infections in December 2020, the desperate need for access to an 
efficacious vaccine was amplified. The emergence of a new variant 
of SARS-CoV-2 (501Y.V2) in the country since October 2020[1] 
increased transmissibility by 50%,[2,3] probably magnifying the second 
wave, during which there was a sharp increase in infections and 
hospitalisations. It was clear that an efficacious vaccine was necessary, 
but would low- and middle-income countries (LMICs) receive 
supplies sufficient to meet demand? This question raised global 
debate on how access to COVID-19 vaccines would be equitably 
distributed on a worldwide scale at a time when all countries required 
vaccines with simultaneous urgency to preserve life and minimise 
disease, protect health systems and reduce transmission.[4-6]
Global justice and COVID-19 vaccine 
access
Unsurprisingly, inequality in access to COVID-19 vaccines has raised 
concerns globally. Despite calls for solidarity and social justice during 
the pandemic, vaccine nationalism and stockpiling of limited vaccine 
supplies by high-income countries (HICs) have brought into sharp 
focus global health inequities and the plight of LMICs as they wait 
in line for small tranches of vaccines. HICs have bought up or are 
busy buying up vaccine stocks in advance.[7] Data suggest that some 
HICs have purchased more than four times the quantity of vaccine 
doses that have been secured by the COVAX facility,[8] which is jointly 
hosted by the World Health Organization (WHO), the Coalition 
for Epidemic Preparedness Innovations and the Global Alliance for 
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Access to COVID-19 vaccines has raised concerns globally. Despite calls for solidarity and social justice during the pandemic, vaccine 
nationalism, stockpiling of limited vaccine supplies by high-income countries and profit-driven strategies of global pharmaceutical 
manufacturers have brought into sharp focus global health inequities and the plight of low- and middle-income countries (LMICs) as 
they wait in line for restricted tranches of vaccines. Even in high-income countries that received vaccine supplies first, vaccine roll-out 
globally has been fraught with logistic and ethical challenges. South Africa (SA) is no exception. Flawed global institutional strategies 
for vaccine distribution and delivery have undermined public procurement platforms, leaving LMICs facing disproportionate shortages 
necessitating strict criteria for vaccine prioritisation. In anticipation of our first consignment of vaccines, deliberations around phase 1 
roll-out were intense and contentious. Although the first phase focuses on healthcare personnel (HCP), the devil is in the detail. Navigating 
the granularity of prioritising different categories of risk in healthcare sectors in SA is complicated by definitions of risk in personal and 
occupational contexts. The inequitable public-private divide that characterises the SA health system adds another layer of complexity. 
Unlike other therapeutic or preventive interventions that are procured independently by the private health sector, COVID-19 vaccine 
procurement is currently limited to the SA government only, leaving HCP in the private sector dependent on central government allocation. 
Fair distribution among tertiary, secondary and primary levels of care is another consideration. Taking all these complexities into account, 
procedural and substantive ethical principles supporting a prioritisation approach are outlined. Within the constraints of suboptimal global 
health governance, LMICs must optimise progressive distribution of scarce vaccines to HCP at highest risk.
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Vaccines Initiative to support access for LMICs.[9-11] In fact, countries 
such as Canada and the UK, and others, have secured vaccine doses 
in numbers that are up to five times more than their populations, 
when most LMICs have not yet secured any vaccines, an inequity the 
WHO Director-General, Dr Tedros Ghebreyesus, has described as ‘a 
catastrophic moral failure’.[12] This situation has prompted a call for 
HICs to release excess vaccine for use in LMICs desperate to acquire 
vaccine.[13]
In addition to vaccine supplies via the COVAX facility[8] and 
the African Union, SA was able to source an initial supply of the 
AstraZeneca-Oxford vaccine under the tradename Covishield, from 
the Serum Institute of India. By the end of January 2021, 1 million 
doses of the vaccine had arrived, at a cost of USD5.25 per dose, 
more than double the USD2.16 per dose paid by European Union 
countries.[14] Disappointingly, SA was unable to secure a fair pricing 
agreement despite hosting a clinical trial of the AstraZeneca vaccine, 
violating the principles of post-trial access for communities and 
benefit sharing in research, and raising queries around researcher 
responsibilities and reviews by research ethics committees.[15] Notably, 
the lack of transparency in bilateral agreements has meant that 
national governments have not been able to negotiate the fairest deals 
in accessing vaccine for their populations, which has undermined 
the global solidarity needed between countries to ensure an equitable 
distribution of vaccine.
However, the results of the local arm of the study raised concerns 
that the AstraZeneca vaccine would not protect against the 501Y.
V2 variant. Given that participation was limited to young adults, 
generalisability was limited, as results could only be extrapolated 
to the lack of prevention of mild and moderate disease and not to 
prevention of severe disease.[16] Subsequently, the Johnson & Johnson 
COVID-19 vaccine was adopted for roll-out in the form of a phase 
3B ‘implementation trial’. As it is an open-label trial, all participants 
are offered an active vaccine.
Global distribution of vaccines
From an ethics perspective, conceptual attempts at global distribution 
have been proposed, most notably the ‘Fair Priority Model’ that 
describes three fundamental values – benefit and minimising harm, 
prioritising the disadvantaged, and equal moral concern.[17] An 
early WHO approach recommended that countries receive doses in 
proportion to between 3% and 20% of their populations.[17,18] This 
type of distribution could be challenging if population age and risk 
are taken into account. Proportionality may also be considered in 
relation to burden of COVID-19 disease, raising the ethical challenge 
of allocating more vaccine to countries that have managed the 
pandemic poorly than to those that have implemented strong public 
health containment measures.[17] National burden of all-cause disease 
is, however, another consideration. SA has a high burden of diseases 
that increase the risk of developing severe COVID-19 infection, 
including tuberculosis, HIV and non-communicable diseases.[19] This 
disease burden should be considered in global vaccine distribution 
strategies based on proportionality.
At a national level, given that global demand will outstrip supply, 
many countries have opted for a phased distribution of efficacious 
vaccines.
Incremental vaccine distribution:  
A phased approach
Global inequality in the governance of vaccine availability has created 
conditions that present LMICs with thankless choices regarding 
prioritisation. Firstly, vaccine producers have not played ball with 
enabling technology transfer but kept their intellectual property 
tightly under their control, as shown by their unwillingness to 
support the WHO COVID-19 Technology Access Pool.[20,21] Had this 
been handled differently from the start, we would not be reliant on 
merely a few producers, and though we would probably still have had 
to ration vaccine, the extent of rationing would probably be neither 
as brutal or as chaotic.
Secondly, we are waiting in a vaccine procurement queue 
determined by power and money, shrouded in secrecy and in 
circumstances beyond the control of most LMICs. The Johnson & 
Johnson vaccine is slated to arrive in tranches of 80 000 doses every 2 
weeks, which means that SA has not yet secured sufficient doses for 
all its health personnel. As a result, we are faced with deciding which 
health personnel go to the back of the first queue without being sure 
if we will ever get to the end of that queue in phase 1.
Thirdly, while SA has managed to extract some vaccine for itself, 
what of other less wealthy and less politically influential countries 
in Africa, for which vaccination looms as a distant likelihood only 
in 2022 or 2023?[22] That is a reflection of the weakness of global 
institutions for vaccine access. This global inequality has given SA 
limited options (and other African countries even fewer options) 
within which we have to prioritise. In considering the ethical choices 
for incremental vaccine distribution, we therefore need to constantly 
locate these difficult choices in a political context of global inequality 
rather than solely in wrong decisions by LMIC policy makers, 
governments, health services or ethicists.
Three major vaccine allocation frameworks that include national 
allocation criteria merit noting – the WHO Strategic Advisory Group 
of Experts,[23] the National Academies of Science Engineering and 
Medicine[24] approach and the Centres for Disease Control guideline.[25]
All guidelines underscore the moral legitimacy of priority-setting 
in the context of this pandemic by including principles relating to 
procedural justice.[26] A fair process for allocating scarce resources 
requires decision-making that is: (i) transparent in how allocation 
is made and what prioritisation criteria are used; (ii) inclusive of 
affected stakeholders; (iii) consistent in how it treats persons in the 
same category; and (iv) accountable to the public.
The National Academies framework is comprehensive. Central to 
the framework are important substantive aspects based on the risk 
of acquiring and transmitting infection, prevention of morbidity and 
mortality, and negative societal impact. A stakeholder engagement 
process is highlighted and the uncertainty regarding efficacy and safety 
of COVID-19 vaccines in children, pregnant women, older adults 
and those who have had natural infection with COVID-19 is flagged. 
Solidarity and social responsibility are embraced, where countries with 
vaccine manufacturing capability are expected to provide for their 
own citizens first, but also allocate a proportion of the supply to other 
countries.[24] Uncertainty related to vaccine efficacy and the emergence 
of new variants could be added to their list.[27]
All prioritisation frameworks include HCP in phase 1, which 
reflects global consensus that HCP ought to be first in line to receive 
the vaccine. This choice rests on multiple premises. Firstly, this group 
is at increased occupational risk owing to exposure to high viral loads 
from the volume of patients presenting for treatment during the 
pandemic. Globally, many HCP have been infected, have died or have 
survived with physical or psychological sequelae.[28,29] Given the pre-
existing HCP shortage in LMICs, countries such as SA cannot afford 
to lose any more health staff without risking serious compromise 
to quality of care in health facilities. By protecting HCP, the health 
system is indirectly protected. HCP have instrumental value that 
is both retrospective (based on the patient lives already saved, and 
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prevention and treatment of illness) and prospective (based on 
potential lives saved and illness prevented and treated in the future).
It may be argued that many HCP are just doing their jobs, which 
carry inherent risk, which therefore should attract no additional 
entitlement to preferential treatment. However, this risk was 
significantly elevated during the pandemic, and many went beyond 
their scope of duty by working outside their usual disciplines, working 
longer hours and sacrificing leave and other benefits, among others. 
Some returned from retirement, assisting in casualty departments 
and doing ward rounds in hospitals. On a personal level, some also 
made sacrifices that transcended regular personal compromises to 
family time, such as living separately and minimising contact to 
protect their families due to unanticipated elevated occupational risk. 
These factors justify priority access to vaccines based on reciprocal 
obligation, as reciprocity in this context requires protection of those 
who ‘bear significant additional risks and burdens of COVID-19 to 
safeguard the welfare of others’.[23]
Likewise, the SA approach[30] includes a broad framework with 
three phases (Table 1).
Unique to the SA framework is the inclusion of traditional healers 
in phase 1. In the SA context, ~60% of the population consult 
traditional healers before approaching the allopathic health system. 
There are ~200 000 traditional healers in the country.[31] It is assumed 
that those who are registered with the Department of Health (DoH) 
in terms of the Traditional Health Practitioners Act 2007 (No. 22 of 
2007) will be included in the phase 1 roll-out. During the pandemic 
the DoH issued guidelines for traditional practitioners to assist them 
with pandemic prevention measures and to promote community 
education.[32]
Broad frameworks are often a point of departure in vaccine 
prioritisation. Phase 1, however, requires further attention with 
regard to the granularity inherent at several levels.
Ethical considerations in phase 1 
vaccine allocation
Fairness in public-private sector allocation
Given the dual healthcare system in SA, phase 1 guidance specifies 
that both public and private health sectors must be included. Ideally, 
both sectors ought to be covered completely, based on the number of 
HCP at risk, especially because the private sector was not at liberty 
to procure vaccine supplies. However, when supplies are scarce, how 
should limited vaccines be fairly distributed between these two health 
sectors?
As a point of departure, one needs to decide whether the 
prioritisation approach is based on protecting HCP or preserving 
health systems. If preservation of the latter is the primary goal, a 
decision must be taken on whether the different health systems 
are being preserved for the acute COVID-19 wave or for their 
general health functions. The latter option would justify using 
dependent populations as a more appropriate metric. Pre-pandemic 
data indicated that ~20% of the SA population receives healthcare 
in the private sector, while the public health sector attends to ~80% 
of the population.[33] Short- to medium-term preservation of health 
systems for COVID-19 would, however, only consider the number 
of patients treated in each sector for COVID-19. During the peak 
of the pandemic waves, both healthcare sectors were overwhelmed, 
especially during the second wave, with patients being cross-referred 
when necessary.[34] However, while both sectors used standardised 
guidelines for intensive care unit (ICU) admission, length of stay 
differed, with the private sector able to accommodate critical care 
patients for longer due to more critical care beds being available. 
However, outpatients also need to be taken into account. Also, many 
patients who usually use the public health sector were paying to 
receive treatment for COVID-19 and other diseases in the private 
sector via general practices.
Given the lack of accurate data on actual numbers of patients 
treated in the private and public sectors during the pandemic and 
the lack of equivalence of clinical decision-making given differences 
in resources available, decision-making around fair rationing of 
suboptimal vaccine doses between the health sectors is compromised. 
Therefore, if the underlying rationale in prioritisation is based on 
protecting HCP and not necessarily health systems, using the number 
of HCP across both sectors is a reasonable alternative metric that 
could be used.
Prioritisation based on occupational and personal risk
In addition to the private-public distribution dilemma, occupational 
risk would justify further prioritisation across all health sectors. 
Occupational risk would include a spectrum of exposure ranging 
from extremely high-risk roles (such as performing aerosol-
generating procedures, working in critical care environments, having 
direct contact with high volumes of COVID-19-positive patients 
for prolonged periods in COVID-19-specific wards, and testing for 
COVID-19) to high- to moderate-risk roles (such as screening in 
outpatient departments and general practice, working in the hospital 
laundry or mortuary, and cleaning) and lower-risk work with no 
direct patient contact (such as provision of support/administrative 
services).
Similar to other countries, SA has further stratified occupational 
risk as follows: 
• Category 1a. Those conducting aerosol-generating procedures, e.g. 
intubation, ventilation, taking COVID-19 specimens
• Category 1b. Those in direct contact with known or suspected 
COVID-19 patients
• Category 1c. Those in contact with patients (not known/suspected 
to have COVID-19)
• Category 2. Those not in contact with patients.
This substratification of occupational risk is important. However, 
when vaccine supplies are extremely limited, personal risk ought to 
be considered as well.
Key to fair allocation, especially when not all can receive a vaccine 
in phase 1 of prioritisation frameworks, would be an objective 
measure of personal and occupational risk within healthcare 
environments and institutions. Personal risk factors would include 
age, comorbidities, previous COVID-19 infection and risk to family. 
Previous COVID-19 infection has become contentious, given the 
emergence of variants and uncertainty about the duration and quality 
Table 1. Phased vaccine rollout plan in South Africa
Phase 1 Frontline healthcare personnel in the public and private health sectors, home care workers and traditional healers
Phase 2 Essential workers (teachers, police, military); those in congregate settings (elderly care homes, shelters and prisons); adults 
aged >60 years; and those aged >18 years with comorbidities
Phase 3 All other adults aged >18 years not included in phases 1 and 2
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of immune protection after natural infection. Given some degree of 
anticipated post-infection immunity, in situations of extreme vaccine 
scarcity it is preferable to delay vaccination of those HCP who have 
had a recent infection (for example, within 2 - 3 weeks of vaccine 
roll-out). These HCP would be eligible for vaccination later when 
further vaccine supply becomes available, thereby preserving earliest 
vaccination for those HCP who could benefit the most.
Contextualised COVID-19 vaccine 
allocation approaches for HCP (phase 1)
Allocation approach 1
In an ideal setting, a combination of personal and occupational risk 
factors could be built into an algorithm or matrix (vulnerability v. 
risk) and administered on a digital platform for all HCP to score 
themselves. Non-digital scoring is also possible. These scores could 
assist in prioritising those at highest risk for early vaccine allocation 
across primary, secondary and tertiary levels of care in the public 
and private healthcare sectors. Appointments for vaccination could 
be based on prioritising HCP with the highest scores. This approach 
may have the indirect benefit of staggering vaccination in specific 
environments to prevent interruption in healthcare provision in the 
event of post-vaccine side-effects.
Allocation approach 2
In countries or settings where individual scoring on digital or non-
digital platforms is not feasible, a different approach to vaccine 
allocation may be necessary. In such contexts, one could move from 
individual risk assessment to environmental risk assessment. Using 
this approach, environments classified as high risk would result in 
all personnel working there being eligible for early vaccination. For 
example, all personnel in ICUs, high-care units, COVID-19 wards, 
emergency/casualty/outpatient units or emergency response services, 
testing facilities, vaccinating teams and other high-risk environments 
in hospitals and clinics would be prioritised. This approach would 
apply across public and private health settings and could logistically 
be relatively easy to implement. As further vaccine supplies become 
available, other environments would be progressively included. This 
approach would favour hospital-based tertiary healthcare in the early 
stages of vaccine roll-out, which raises questions of equity.
Allocation approach 3
Yet another approach could include allocation to specific categories 
of HCP based on occupational role, with preference in each category 
given to patient-facing staff. Such an approach could start with 
emergency services (including ambulance staff) and progress to 
nurses, then doctors, or vice versa, depending on risk in different 
contexts.[29] Other patient-facing health professionals could then be 
incrementally included. In some contexts, nurses were found to be at 
higher risk of contracting infection, while doctors were at higher risk 
of death.[29] Based on numbers supplied by institutions, vaccine doses 
would be dispatched to specific institutions.
Irrespective of which approach is used, a further consideration at 
the outset requires a plan regarding protecting vaccinating teams, 
who would require priority immunisation so that they can proceed 
with vaccination at scale. In some contexts, this may include senior 
health science students who have been trained to administer vaccines.
Avoiding or minimising vaccine 
wastage
Important in such an approach would be avoidance of vaccine 
wastage as an ethical imperative under conditions of vaccine scarcity. 
This implies that a vaccine allocation approach ought to start by 
identifying the number of those who will decline vaccination, for 
whatever reasons, and procuring only sufficient supplies for those 
who will accept vaccines. Once vaccines are received at vaccinator 
sites, it is important to ensure adherence to specific protocols to avoid 
vaccine wastage. Given that many of the COVID-19 vaccines will be 
distributed in multidose vials, a level of flexibility may be required 
at vaccinator sites to avoid wastage. Where vaccines are at risk of 
expiring or cold-chain disruption, it would be prudent to ensure that 
vaccine doses are administered to those willing to accept vaccination 
rather than discarding valuable doses.
Vaccine acceptance among HCP
SA has had a history of reasonable childhood immunisation 
coverage, reaching ~82% prior to the pandemic.[35] However, a 
recent Ipsos survey commissioned by the World Economic Forum 
has demonstrated that only 64% of South Africans would accept 
a COVID-19 vaccine.[34] While the validity of generalising these 
findings is unclear, vaccine hesitancy is growing in prominence in 
Africa.[36] Globally, vaccine acceptance rates among HCP have been 
estimated to be ~70 - 80%,[37] while estimates in SA are ~67%.[38] 
Vaccine acceptancy is dynamic and context-specific and is likely to 
evolve as vaccine roll-out progresses. Health workers, in particular, 
are regarded as role models for improving population uptake.
Mandatory vaccination in health 
environments
Currently, given the fact that vaccine access is part of an 
implementation trial, participation remains completely voluntary. 
Even if the Johnson & Johnson vaccine is registered under section 
21 regulations (equivalent to Emergency Use Authorisation in 
other countries) and non-research-related roll-out commences, 
participation will still be voluntary. Mandatory vaccination will only 
be an option when a COVID-19 vaccine has full registration with the 
South African Health Products Regulatory Authority.
Given that HCP could decline COVID-19 vaccination for a number 
of reasons, there would be implications in the healthcare setting both 
for patients and staff. Ethical and professional obligations highlight 
patient safety, which is fundamental to the foundational principle of 
healthcare ethics: first do no harm or primum non nocere. Likewise, 
reducing risk to colleagues in the healthcare environment would 
be regarded as an ethical and legal obligation. The SA Constitution 
(1996) in section 23 indicates that ‘Everyone has a right to fair labour 
practices’.[39] This includes employers and employees. Consequently, 
employers would need to institute policies to ensure a safe working 
environment for all. Although the preferable approach would include 
encouragement and counselling of all staff regarding the benefits of 
vaccination, there would be legal and human rights considerations 
that must be taken into account in the context of public interest, 
the Disaster Management Act (No. 57 of 2002)[40] and the National 
Health Act (No. 61 of 2003).[41] Competing entitlements in the Bill 
of Rights can be resolved through appropriate application of section 
36 of the Constitution that provides for conditions under which 
limitation of rights in the interests of the public good may occur.
Conclusions
Widespread inadequacies in global health governance have contri buted 
to disproportionate vaccine distribution, forcing LMICs, including 
SA, to make difficult prioritisation decisions. Prioritising allocation 
of extremely limited vaccine supplies raises all the quintessential 
challenges of distributive justice. A legitimate COVID-19 vaccine 
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prioritisation plan must be built on fundamental ethical principles. In 
SA, justice in phase 1 distribution requires that all health personnel 
at risk in the public and private sectors, delivering care at primary, 
secondary and tertiary levels, are treated fairly and consistently. 
Operational and ethical challenges are inextricably intertwined, 
and in LMICs, compelling arguments exist for contextualising 
prioritisation approaches. Given the high emotions, concerns and 
anxieties seen during and after the second wave of COVID-19 in SA, 
prioritisation is necessary but raises the risk of divisions and mistrust 
at multiple levels – within the healthcare community in general as 
well as in the public and private health sectors. In the context of 
extreme vaccine scarcity, transparent, rational allocation approaches 
are important to legitimise phase 1 roll-out and improve vaccine 
uptake. Ultimately, reforms in global health governance are urgently 
needed to improve vaccine access in LMICs.
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